Delivery Order SPE2DB22D3301-SPE2DB25FX8YD

Award Date 1/24/25
Potential Completion Date 2/14/25
Potential Value $13K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $12,697.69, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of TUKYSA 150 MG TABLET, a pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,191.88 delivery order is for the supply of the medication TUKYSA 50 MG TABLET UU 60S. The contract has a firm fixed-price pricing type and an ultimate completion date of November 6, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office division is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999 through December 2025. The $12,251.30 delivery order is for the supply of TUKYSA 150 MG TABLET UU 60S, a pharmaceutical product, to support military treatment programs and facilities worldwide. The contract is a Firm Fixed Price arrangement with no...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of the drug TUKYSA 150 MG TABLET, a specialty medication, with a ceiling value of $25,395.38 and a period of performance through May 5, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger...
This contract award, with an ID of SPE2DB22D3016|SPE2DB23FBPH7, was issued by the Defense Logistics Agency (DLA) to the Amerisourcebergen Drug Corp's Corporate Office Division. The $24,502.60 firm fixed-price delivery order is for the supply of 4561879459 - TUKYSA 150 MG TABLET UU 60S, with a completion date of September 11, 2023. Amerisourcebergen, a major pharmaceutical distribution company, holds a single-award Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, with a ceiling value of $12,273.50, is for the supply of the pharmaceutical product TUKYSA 150 MG TABLET UU 120S. The contract is a Delivery Order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC), which has a maximum potential value of $999,999,999.00 and enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide TUKYSA 150 MG TABLET UU 60S pharmaceuticals. The $18,376.95 order is scheduled for completion by January 18, 2024. Amerisourcebergen Drug Corp, a for-profit organization, is the prime contractor and has delivered pharmaceuticals, medical supplies, and related distribution services to the DLA previously under indefinite delivery...
This federal contract award, with ID SPE2DB22D2206|SPE2DB24FJY70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the prescription medication TUKYSA 150 MG TABLET. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $18,376.95 and an ultimate completion date of September 16, 2024. This award is not associated with any set-aside program. AmerisourceBergen, through its Corporate Office...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract (IDC) valued at $999,999,999. The contract covers a wide range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to support military healthcare programs globally. The delivery order has...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $26,745.19, is a delivery order from the Defense Logistics Agency (DLA) Troop Support Medical division, a defense agency that supports military healthcare programs. The contract is for the delivery of Tivicay 50 mg tablets, a prescription medication, with an ultimate completion date of July 19, 2024. The contract is a firm fixed-price...
  • SPE2DB22D3301
    Indefinite Delivery Contract
  • SPE2DB22D3301-SPE2DB25FX8YD
    Delivery Order

This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,613.24, is for the supply of TUKYSA 50 MG TABLET to support federal healthcare programs.

The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to military treatment facilities, veterans' healthcare programs, and other federal medical institutions. The contract does not have a set-aside designation, indicating open competition.

In addition to the DLA contract, AmerisourceBergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 4/25/25, 10:44 AM